Filippo G. de Braud

Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC.

A. Shaw, E. Felip, F. D. De Braud, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.

P. Ascierto, P. Ott, M. Pietanza, 2015 .

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.

M. Fassan, F. D. De Braud, G. Curigliano, 2020, The oncologist.

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)

C. De Marco, U. de Giorgi, G. Procopio, 2024, Therapeutic advances in medical oncology.

Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.

A. Drilon, G. Demetri, M. Ahn, 2020 .

Unleashing precision: a review of targeted approaches in pleural mesothelioma.

C. D. Della Corte, G. Viscardi, G. Lo Russo, 2024, Critical reviews in oncology/hematology.

Targeted treatments in advanced renal cell carcinoma: focus on axitinib

R. Iacovelli, G. Procopio, F. de Braud, 2014, Pharmacogenomics and personalized medicine.